Sec. 704. Prostate cancer detection research and education
873 words·~4 min read·
/bill/116/s/4819/is/section-704A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
This section may be cited as the . Prostate Cancer Detection Research and Education Act The Secretary of Health and Human Services (referred to in this section as the Secretary ), acting through the Director of the National Institutes of Health, shall establish an advisory council on prostate cancer (referred to in this section as the advisory council ) to draft a plan for the development and validation of an accurate test or tests, such as biomarkers or imaging, to detect and diagnose prostate cancer.
The advisory council shall be comprised of the following experts: A designee of the Centers for Disease Control and Prevention. A designee of the Centers for Medicare & Medicaid Services. A designee of the Office of the Director of the National Cancer Institute. A designee of the Director of the Department of Defense Congressionally Directed Medical Research Programs. A designee of the Director of the National Institute of Biomedical Imaging and Bioengineering. A designee of the Director of the National Institute of General Medical Sciences.
A designee of the Director of the National Institute on Minority Health and Health Disparities. A designee of the Office of the Director of the National Institutes of Health. A designee of the Food and Drug Administration. A designee of the Agency for Healthcare Research and Quality. A designee of the Director of the Telemedicine and Advanced Technology Research Center of the Department of Defense. In addition to the members described in clause (i), the advisory council shall include 8 expert members from outside the Federal Government to be appointed by the Secretary, which shall include— 2 prostate cancer patient advocates; 2 health care providers with a range of expertise and experience in prostate cancer; and 4 leading researchers with prostate cancer-related expertise in a range of clinical disciplines.
The advisory council shall meet quarterly and such meetings shall be open to the public. The advisory council shall advise the Secretary, or the Secretary’s designee. Not later than 1 year after the date of enactment of this Act, the advisory council shall provide to the Secretary, or the Secretary’s designee, and Congress— an initial evaluation of all federally funded efforts in prostate cancer research relating to the development and validation of an accurate test or tests to detect and diagnose prostate cancer; a plan for the development and validation of a reliable test or tests for the detection and accurate diagnosis of prostate cancer; and a set of standards for prostate cancer screening, developed in coordination with the United States Preventive Services Task Force, to ensure that any tools for screening, detection, and diagnosis developed in accordance with the plan under clause
(ii)will meet the requirements of the Task Force for recommendation as a proven preventive or diagnostic service. The advisory council shall terminate on December 31, 2024. Notwithstanding any other provision of law, the Secretary may make available $1,000,000, from any unobligated amounts appropriated to the National Institutes of Health, for each of fiscal years 2021 through 2025 to carry out this subsection. The Director of the National Institutes of Health, in consultation with the Secretary of Defense, shall coordinate and intensify research in accordance with the plan provided under subsection (b)(2)(D)(ii), with particular attention provided to leveraging existing research to develop and validate a test or tests, such as biomarkers or imaging, to detect and accurately diagnose prostate cancer in order to improve quality of life for millions of individuals in the United States, and decrease health care system costs. Notwithstanding any other provision of law, the Secretary may make available $30,000,000, from any unobligated amounts appropriated to the National Institutes of Health, for each of fiscal years 2022 through 2026 to carry out this subsection. The Secretary, in coordination with the Director of the National Institutes of Health and the Director of the Centers for Disease Control and Prevention, shall carry out a national campaign to increase the awareness and knowledge of prostate cancer. The national campaign conducted under paragraph
(1)shall include— roles for the National Cancer Institute, the National Institute on Minority Health and Health Disparities, the Office of Minority Health of the Department of Health and Human Services, and the Office of Minority Health and Health Equity of the Centers for Disease Control and Prevention; and the development and distribution of written educational materials, and the development and placing of public service announcements, that are intended to encourage men to seek prostate cancer screening when symptoms are present, when they have a family history of prostate cancer, or if they belong to a high-risk population. In developing the national campaign under paragraph (1), the Secretary shall recognize and address— the racial disparities in the incidences of prostate cancer and mortality rates with respect to such disease; and any barriers in access to patient care and participation in clinical trials that are specific to racial minorities. The Secretary shall establish a program to award grants to nonprofit private entities to enable such entities to test alternative outreach and education strategies to increase the awareness and knowledge of individuals in the United States with respect to prostate cancer. There is authorized to be appropriated to carry out this subsection, $5,000,000 for each of fiscal years 2021 through 2025.